The CrossFAST 6F FDA clearance gives interventional cardiologists a larger-lumen version of a microcatheter system built for difficult coronary procedures. On 13 October 2026, Vantis Vascular announced that the US Food and Drug Administration (FDA) cleared the 6 French (6F) model of its CrossFAST Integrated Microcatheter Advanced Delivery System through the 510(k) pathway. The clearance itself is dated 18 September 2026, so the announcement disclosed a milestone that was already about three and a half weeks old.
This is a new configuration of an existing device, not a new treatment category, and the release reports no clinical data. Below we explain what changed, what the clearance does and does not mean, and when the product is expected to reach hospitals.
Key takeaways
- The FDA cleared the 6F CrossFAST model on 18 September 2026 under 510(k) number K262817; Vantis announced it on 13 October.
- The 6F version has a larger internal lumen and a shorter distal tip, which the company says suits a wider range of devices in complex percutaneous coronary intervention (PCI).
- Commercial availability is expected in November 2026, alongside the existing model.
- The announcement contains no clinical trial, outcome or comparative data.
What the CrossFAST 6F FDA clearance covers
CrossFAST is a two-part system. According to the company, DuoPRO Interlocking Technology couples an inner monorail microcatheter with an outer delivery catheter so they advance together as one unit. It is used with guide catheters, the tubes that carry equipment toward the heart’s arteries, to reach narrow or tortuous regions of the coronary or peripheral blood vessels and help place interventional devices.
The new 6F model changes two things. First, the lumen, the hollow channel through the catheter, is larger. The company says that lets operators use a broader range of devices, including intravascular ultrasound (IVUS) imaging catheters and intravascular lithotripsy (IVL) catheters, which use sound-wave pulses to crack calcified plaque. Second, the distal tip is shorter. The release does not give lumen dimensions, tip lengths or compatibility tables, so readers should consult the product labelling for specifics.
The system has been sold in the United States since January 2025 in a 5.5F size. The 6F model joins it rather than replacing it. FDA’s FDA clearance letter for the first model, dated September 2024, lists that earlier model under a slightly different name, a guide extension system.
Timing of the CrossFAST 6F FDA clearance versus the announcement
The dates are easy to mix up. FDA clearance for the CrossFAST 6F came on 18 September 2026. The public announcement came on 13 October 2026. Anyone reading the news as an FDA action taken this week would be mistaken. Vantis also expects commercial availability in November 2026, which is a company plan and could shift. Until the product ships, the clearance means the device may be legally marketed, not that it is in use.
What a 510(k) clearance means for the CrossFAST 6F FDA clearance
Under FDA’s 510(k) program, a company shows that its device is substantially equivalent to a legally marketed predicate, with the same intended use and either the same technology or differences that raise no new safety or effectiveness questions. FDA calls the outcome a clearance, not an approval. A 510(k) does not require clinical trials in every case; performance data can be bench testing as well as clinical evidence. So the CrossFAST 6F FDA clearance tells us the device met that standard. It does not tell us it improves patient outcomes compared with other tools.
Who might use it and why the details matter
Complex PCI covers cases such as heavily calcified lesions or winding vessels, where delivering a stent or imaging catheter can be hard. Jasvindar Singh, MD, an interventional cardiologist at Washington University and Barnes-Jewish Hospital in St. Louis, said in the company’s release that the larger lumen lets him use CrossFAST in more of the complex cases he performs. That is one physician’s view, quoted by the manufacturer, not evidence of broader benefit. Chief executive Jason Turner said the company aims to help physicians go faster and further during coronary interventions, which is promotional language.
Vantis Vascular is a privately held medical technology company based in San Jose, California, and was founded by physicians, according to the company’s website. Because it is private, there are no public financial disclosures to judge how much commercial weight the 6F model might add.
Our assessment of the CrossFAST 6F FDA clearance
In our assessment, the CrossFAST 6F FDA clearance is a sensible product-line extension: a larger channel lets the same delivery platform carry imaging or plaque-modifying tools that would not fit before, which is where much of today’s complex PCI is heading. The open question is evidence. Without published comparisons on procedure time, success in crossing lesions or complications, hospitals will judge it on operator experience and price. For related device coverage, see our report on Stryker’s $400 million investment in CMR Surgical, or read our market overview of interventional cardiology devices. More device news is in our medical devices section.
Risks and caveats of the CrossFAST 6F FDA clearance
- The release is a company statement; its claims are not independently verified.
- No clinical or comparative data were reported.
- The November 2026 launch date could change.
- Compatibility with specific IVUS and IVL products must be confirmed in the labelling.
What to watch after the CrossFAST 6F FDA clearance
- Confirmation of the US launch in November 2026.
- Physician feedback and any published case series.
- Further size or model additions from Vantis.
Frequently asked questions about the CrossFAST 6F FDA clearance
What did the FDA clear?
A 6 French version of the CrossFAST Integrated Microcatheter Advanced Delivery System, under 510(k) number K262817, according to the company.
When was the clearance granted?
18 September 2026. Vantis announced it publicly on 13 October 2026.
What is new about the 6F model?
A larger lumen and a shorter distal tip, designed for a broader range of devices in complex PCI.
When will it be available?
The company expects commercial availability in November 2026.
Does the clearance show better patient outcomes?
No. A 510(k) shows substantial equivalence, and the announcement included no outcome data.
How we reported this: we relied on Vantis Vascular’s 13 October 2026 announcement, FDA’s published 510(k) information and its 2024 clearance letter for the first model. These are company statements unless noted. Last updated: 14 October 2026. This article is news reporting and not medical advice.
